According to latest report, the global antiviral combination therapies market value reached at US$ 40.5 Bn in 2020 and projected to hit US$ 71.2 billion by 2030.
Antiviral combination therapies are drugs developed using a combination of two or more drugs for the treatment of various viral diseases, including chronic hepatitis B, hepatitis C, and HIV. Combination antiretroviral therapy aids in stopping the virus from making multiple copies of itself in the body.
The global antiviral combination therapies market is driven by significant growth in spending on research & development by market players for the development of effective antiviral combination therapies for the treatment of a range of viral diseases; ability of the combination therapy to control the antibiotic resistance, and increase in focus on drug repurposing and vaccine development for the treatment of COVID-19.
Multiple Antiviral Drugs Prove More Effective in Treatment of COVID-19 than Single Drugs
The triple combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b holds promising potentials in the treatment of coronavirus (COVID-19). Researchers in healthcare companies and organizations are referring historical findings of the lopinavir-ritonavir & ribavirin combination, which was effective in lowering the morbidity and mortality rate of the then SARS (Severe Acute Respiratory Syndrome). Since COVID-19 is a novel viral infection, companies in the antiviral combination therapies market are increasing their research in triple combination therapies to advance in the coronavirus treatment.
Many Coronavirus patients are in need for intensive respiratory support in hospitals. Since lopinavir–ritonavir and interferon beta-1b were found to reduce the viral load in SARS, companies in the antiviral combination therapies market are increasing focus in these drugs to innovate in antiviral drugs for coronavirus. It has been found that multiple antiviral drugs help to improve patient outcomes as compared to the consumption of single drug treatments.
Strategic Collaborations Help Increase Combination Therapy Trials for Combating Coronavirus
Companies in the antiviral combination therapies market are taking giant strides by increasing their trails to combat COVID-19. The Indian Institute of Chemical Technology (IICT) has joined forces with the Indian subsidiary of global pharmaceutical company, Mylan, to innovate in combination therapies for coronavirus. Many pharmaceutical companies in India have entered the Phase 3 of clinical trials with the help of computational modelling of molecules and laboratory-based data. The unprecedented demand for antiviral drugs has fueled innovations in combination therapy trials. Moreover, rising COVID-19 cases in India is acting as a key driver for market growth.
Medical institutes are increasing efforts to collaborate with hospitals to innovate in combination therapy trials. It has been found that the combination of antiviral drugs with antibiotics holds promising potentials in minimizing coronavirus symptoms in patients.
Traditional Chinese Medicine with Entecavir Reduces Morbidity in Hepatitis B Patients
The antiviral combination therapies market is projected to advance at a high CAGR during the assessment period. Healthcare companies are exploring new therapy avenues such as the combined therapy of traditional Chinese medicine (TCM), along with antiviral drugs for the treatment of chronic hepatitis B (CHB). The Chinese YinQiSanHuang-antiviral decoction with entecavir is gaining popularity for reducing the annual incidence of liver fibrosis/cirrhosis amongst hepatitis B patients. Thus, analysts of Transparency Market Research (TMR) anticipate that the antiviral combination therapy is a fast growing phenomenon for hepatitis B treatment.
It has been found that conventional antiviral drugs alone are not enough for the efficacious hepatitis B treatment. As such, there is a need for credible clinical evidence to understand the combination of TCM and Western medicines for the hepatitis B treatment.
Small Molecule Antagonists Combined with Oral Antivirals for Hepatitis Treatment
The combination therapy with lamivudine or tenofovir and pegylated interferon (PEG-IFN) has been reported for the treatment of hepatitis B. As such, there is a need for clarification on clinical evidence to analyze the long-term efficacy of this type of combination therapy for CHB. Hepatitis B patients with low hepatitis B surface antigen (HBsAg) levels are being recommended with the combination therapy. However, the scientific community is faced with challenges such as restrictions in research project funds, which breaks the long-term continuity of trial periods. Hence, companies in the antiviral combination therapies market should increase their research expenditure to explore new combination therapies based on different mechanisms.
New drug developments are in pipeline for companies in the antiviral combination therapies market. In November 2018, Gilead Sciences— the U.S. biopharmaceutical company, announced that combination of GS-9688— an investigational oral selective small molecule agonist and oral antivirals is well tolerated among viral hepatitis patients.
North America dominated the global antiviral combination therapies market in 2019. The U.S. was a major market for antiviral combination therapies in the region in 2019. The expansion of the market in the country can be attributed to the presence of leading players, rise in usage of antiviral combination therapies for treating viral diseases, strong pipeline of drugs, and increase in research on the development of antiviral combination drugs for treatment of COVID-19.
The antiviral combination therapies market in Asia Pacific is expected to expand at a high CAGR from 2020 to 2030 driven by developing countries such as China and India. The growth of the market in the region can be attributed to rise in prevalence of HIV in India and other countries in Asia. Additionally, increase in trials on combining antiviral drugs with HIV drugs for the treatment of patients with COVID-19 contributes to the growth of the market in the region.
In terms of drug combination, the integrase inhibitor/NRTI segment is projected to account for a major share of the global antiviral combination therapies market during the forecast period. This can be attributed to increase in usage of this drug combination in the treatment of HIV. Additionally, patent exclusivity of these drugs drives the segment.
In terms of indication, the global antiviral combination therapies market has been classified into HIV, hepatitis, and others. Globally, in 2019, over 38 million people lived with HIV. Of these, around 36.2 million were adults and 1.8 million were children. Additionally, over 1.7 million individuals acquired HIV in 2019.
Based on route of administration, the global antiviral combination therapies market has been bifurcated into oral and intravenous.
In terms of distribution channel, the global antiviral combination therapies market has been segregated into hospital pharmacies, retail pharmacies, and others.
The global antiviral combination therapies market is fragmented in terms of number of players. Key players operating in the global antiviral combination therapies market are Celltrion, Inc., GlaxoSmithKline plc, Gilead Sciences, Inc., AbbVie, Inc., Bristol-Myers Squibb Company, Janssen Global Services, LLC (pharmaceutical companies of Johnson & Johnson), Cipla, Inc., Mylan N.V., Merck & Co., Inc., and F. Hoffmann-La Roche Ltd.
This report focuses on antiviral combination therapies market includes crucial information on market share, market size, and growth rate for the forecast period 2021 to 2030 at the global level, regional level and company level. From a global perspective, this report represents overall antiviral combination therapies market size by analyzing historical data and future prospect. The study highlights deep analysis on the major drivers of the market, restraints, and challenges to help the business owners, suppliers, and marketing personnel in planning effective strategies for the forecast period. This will help the business and manufacturers to lead the market and gain prominent position in future. The report also presents vital information through graphical representation on factors like table, charts, and statistics. The study includes drivers and restraints of the global antiviral combination therapies market.
The research not only conducts forecasts in terms of value, but also evaluates the market on the basis of essential parameters, such as Year-on-Year (Y-o-Y) growth. This helps providers to recognize the future opportunities as well predictability of the market.
In order to understand and assess opportunities in this market, the report is categorically divided into five key sections on the basis of segments. The report analyzes the global market in terms of value (US$ dollers) and volume (Million Units).
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Every segment is further sub-segmented into several sub-segmented that are deeply analyzed by experts to offer valuable information to the buyers and market players. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
The research report includes a detailed study of regions of North America, Europe, China, Japan and Rest of the World. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2017 to 2030. These analyses will help the reader to understand the potential worth of investment in a particular region.
The report provides in-depth segment analysis of the global antiviral combination therapies market, thereby providing valuable insights at macro as well as micro levels. Analysis of major countries, which hold growth opportunities or account for significant share has also been included as part of geographic analysis of the antiviral combination therapies market.
The report includes country-wise and region-wise market size for the period 2017-2030. It also includes market size and forecast by segments in terms of production capacity, price and revenue for the period 2017-2030.
In this study, the years considered to estimate the market size of antiviral combination therapies are as follows:
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2017 to 2019.
The analysts have provided a comprehensive analysis of the competitive landscape of the global antiviral combination therapies market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation expected to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users) and other segments.
The research methodology adopted by analysts for compiling the global antiviral combination therapies market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global antiviral combination therapies market.
The study objectives of this report are: